Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.
Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.
The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...
Research has revealed that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...
Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...
Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage ...
Hepatitis delta virus testing in those with chronic hepatitis B is low, and improvements are needed to reduce long-term, ...
Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the agreement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback